Egham, UK – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd. Renaissance, a clinical...
finance News
CHICAGO – Esya Labs, which is developing several ground-breaking novel research assays, today has announced that Novartis is among the first companies to use its technology. Novartis, a global healthcare company, has used a patented assay developed by Esya Labs to accelerate drug discovery efforts for Mucolipidosis Type IV, a rare inherited metabolic...
EMERYVILLE, Calif. – Eureka Therapeutics, Inc. announced today that Eureka and Memorial Sloan Kettering Cancer Center (MSK) entered into a license agreement with Sanofi for the non-CAR use of a novel, human binding domain targeting GPRC5D (G Protein-Coupled Receptor Family C Group 5 Member D). The GPRC5D binding domain was discovered using...
EVOTEC AND CHINOOK THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL PRECISION MEDICINES FOR CHRONIC KIDNEY DISEASES COLLABORATION WILL LEVERAGE THE NURTURE PATIENT BIOBANK AND EVOTEC’S MULTI-OMICS PLATFORMS PANHUNTER AND PANOMICS EVOTEC AND CHINOOK AIM TO CHARACTERISE MOLECULAR DRIVERS, IDENTIFY AND VALIDATE NOVEL TARGETS AND DRIVE PATIENT STRATIFICATION...
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited (“Kazia”, ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive...
PHILADELPHIA – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the next phase of its business expansion, including plans to double in size during the next 12 months and opening of business offices in Philadelphia,...
EMERYVILLE, Calif. — XOMA Corporation the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA) acceptance of Zevra Therapeutics’ New Drug Application (NDA) for arimoclomol, an orally-delivered, first-in-class therapy for Niemann-Pick disease type C (NPC), XOMA will make a $1 million milestone payment to...
Washington, DC – The FDA’s safety probe of CAR-T therapies has resulted in a call to add a class-wide boxed warning to these medicines, alerting patients and prescribers of their potential risk of secondary T-cell malignancies. All six commercial CAR-T therapies will be affected, including J&J’s Legend Biotech-partnered Carvykti (ciltacabtagene...
BOCA RATON, Fla. — First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD) such as ulcerative...
Miami — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, announced financial results and recent corporate highlights for the full-year ended December 31, 2022. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief...